Author | Area, subjects | Study design | HPV test | HPV seroprevalence for any and type specific genotypes | HPV seroprevalence of any and type specific genotypes among HIV positive women | Comments |
---|---|---|---|---|---|---|
Newton, et al., 2004) [27] | Mulago hospital, 191 cervical cancer cases and 336 controls; 15 years and older with a new diagnosis of cancer from the wards or outpatient clinics between 1994 and 1998. | Case Control | HPV L1 VLP/ELISA | Cases Type-specific genotypes a HPV 16, 27% HPV 18, 7% HPV 45, 9% Controls Any of 3 HPV typesa, 17% Type-specific genotypes a HPV 16, 11% HPV 18, 5% HPV 45, 6% | HIV Positive Controls Any of 3 HPV typesa, 22% Type-specific genotypesa HPV 16, 16% HPV18, 7% HPV 45, 8% | Antibodies against HPV 16 were significantly associated with cervical cancer OR* = 2.0 (1.2-3.1) The risk increased with increasing anti-HPV 16 antibody titre (Ptrend = 0.01) |
Namujju, et al., 2010 [26] | Naguru and Nsambya Health Centers in Kampala, 2,053 women seeking antenatal services; mean age 23 years (range, 14-48) | Cross-sectional | Serology/VLP ELISA (6, 11, 16,18,31, 33, 45) | Any of the 7 selected HPV typesa, 57% | Â | HIV prevalencea, 7.0% |